中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.011 seconds)

    Extract Of Fraxinus Excelsior Seeds And Therapeutic Applications Therefor
    11.
    发明申请
    Extract Of Fraxinus Excelsior Seeds And Therapeutic Applications Therefor 有权
    Fraxinus Excelsior种子提取物及其治疗应用

    公开(公告)号：US20090117214A1

    公开(公告)日：2009-05-07

    申请号：US12185649

    申请日：2008-08-04

    Applicant: Kan He ,  Marc Roller ,  Antonie Bily ,  Naisheng Bai ,  Jacques Dikansky ,  Alvin Ibarra

    Inventor： Kan He ,  Marc Roller ,  Antonie Bily ,  Naisheng Bai ,  Jacques Dikansky ,  Alvin Ibarra

    IPC: A61K36/63 ,  A61K31/7088 ,  A61P3/00 ,  C07G3/00

    CPC classification number: A61K36/63 ,  A61K31/7088

    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds G15, G13, nuzhenide, and oleoside dimethyl ester.

    Abstract translation: 可以通过阻断脂肪合成，激活PPAR-α，增加降血糖活性，降低体重，控制空腹血浆胰岛素水平与高胰岛素血症的关系，以及促进胰岛素敏感性以及促进胰岛素敏感性的方法，将可以用于治疗受试者（包括人）的Fraxinus excelsior种子提取物 引起有益的急性促胰岛素作用。 Fraxinus excelsior种子提取物尤其包括分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2 - [（6-O-β-D-吡喃葡萄糖基-β-D - 吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）甲酯，通常称为excelside A，分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2- 氧基] -3,4-二氢-5-（甲氧基羰基）-2-（4-羟基苯基）乙酯（通常称为excelside B）的化合物和化合物（6-O-β-D-吡喃葡萄糖基-β-D-吡喃葡萄糖基） G15，G13，nunzhenide和油脂二甲酯。

    EFFECTS OF A DECAFFEINATED GREEN COFFEE EXTRACT ON BODY WEIGHT CONTROL BY REGULATION OF GLUCOSE METABOLISM
    12.
    发明申请
    EFFECTS OF A DECAFFEINATED GREEN COFFEE EXTRACT ON BODY WEIGHT CONTROL BY REGULATION OF GLUCOSE METABOLISM 有权
    通过调节葡萄糖代谢来减少绿色咖啡提取物对身体重量控制的影响

    公开(公告)号：US20150072042A2

    公开(公告)日：2015-03-12

    申请号：US13072648

    申请日：2011-03-25

    Applicant: Alvin IBARRA ,  Marc ROLLER ,  Jacques DiKANSKY

    Inventor： Alvin IBARRA ,  Marc ROLLER ,  Jacques DiKANSKY

    IPC: A23L1/30 ,  A23L1/302 ,  A23L1/304 ,  A23L1/28

    CPC classification number: A61K36/74 ,  A61K31/235 ,  A61K45/06

    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.

    Abstract translation: 一种通过施用一定量的有效治疗受试者的脱咖啡因生咖啡提取物来控制人体重的方法。 优选的生咖啡提取物含有约0.1-约0.2的4-咖啡酰奎宁酸（4-CQA）与总绿原酸（tCGA）（5-CQA / tCGA）的比例。 更优选地，生咖啡提取物包含约6％至约8％的4-咖啡酰奎尼酸，并且总绿原酸浓度超过约45％。 优选的给药方法包括在空腹时在饭前每天给予生咖啡提取物约200mg的剂量。

    Extract of Fraxinus excelsior seeds and therapeutic applications therefor
    14.
    发明授权
    Extract of Fraxinus excelsior seeds and therapeutic applications therefor 有权
    Fraxinus提取物优良种子及其治疗应用

    公开(公告)号：US08293292B2

    公开(公告)日：2012-10-23

    申请号：US13294058

    申请日：2011-11-10

    Applicant: Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques DiKansky ,  Alvin Ibarra

    Inventor： Kan He ,  Marc Roller ,  Antoine Bily ,  Naisheng Bai ,  Jacques DiKansky ,  Alvin Ibarra

    IPC: A61K36/63

    CPC classification number: A61K36/63 ,  A61K31/7088

    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.

    Abstract translation: 可以通过阻断脂肪合成，激活PPAR-α，增加降血糖活性，降低体重，控制空腹血浆胰岛素水平与高胰岛素血症的关系，以及促进胰岛素敏感性以及促进胰岛素敏感性的方法，将可以用于治疗受试者（包括人）的Fraxinus excelsior种子提取物 引起有益的急性促胰岛素作用。 Fraxinus excelsior种子提取物尤其包括分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基-2 - [（6-O- [b] -D-吡喃葡萄糖基 - D-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）甲酯，通常称为excelside A，分离的化合物（2S，3E，4S）2H-吡喃-4-乙酸-3-亚乙基 - 2 - [（6-O-和bgr-D-吡喃葡萄糖基-β-吡喃葡萄糖基）氧基] -3,4-二氢-5-（甲氧基羰基）2-（4-羟基苯基）乙酯，通常称为excelside B ，和化合物GI5，GI3，硝酸ide酯和油甙二甲酯。

Patent Agency Ranking